ACC/AHA Versus ESC Guidelines on Dual Antiplatelet Therapy JACC Guideline Comparison

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

卷:72

Review

Capodanno, Davide¹  Alfonso, Fernando²  Levine, Glenn N.³  Valgimigli, Marco⁴  Angiolillo, Dominick J.⁵ 

[1] Univ Catania, Azienda Osped Univ Policlin Vittorio Emanuele, Div Cardiol, CAST, PO G Rodol, Catania, Italy

[2] Hosp Univ La Princesa, Dept Cardiol, Madrid, Spain

[3] Baylor Coll Med, Dept Med, Houston, TX 77030 USA

[4] Bern Univ Hosp, Bern, Switzerland

[5] Univ Florida, Coll Med, Div Cardiol, Jacksonville, FL USA

关键词: antiplatelet;    bleeding;    stent;    thrombosis;   

DOI  :  10.1016/j.jacc.2018.09.057

来源: Elsevier

【 摘 要 】

Dual antiplatelet therapy (DAPT) is the cornerstone of pharmacological treatment aimed at preventing the atherothrombotic complications in patients with a variety of coronary artery disease (CAD) manifestations. Prescribers of DAPT are confronted with a number of challenges that include selecting the appropriate P2Y(12) inhibitor and determining the optimal duration of DAPT with the scope of minimizing the risk of ischemic and bleeding complications in light of each patient's clinical characteristic and circumstance. Recently, a guideline writing committee from the American College of Cardiology/American Heart Association (ACC/AHA) and a task force from the European Society of Cardiology (ESC) released their respective focused update recommendations on Duration of DAPT in Patients with CAD (ACC/AHA) and DAPT in CAD (ESC). This paper aims to review the ACC/AHA and ESC updates for DAPT to delineate common domains, consistent messages, and differences in recommended management strategies across the Atlantic. (c) 2018 by the American College of Cardiology Foundation.

【 授权许可】

Free